ALDEN SCLERAL ZENLENS: payments to doctors
Payments that named ALDEN SCLERAL ZENLENS as the associated device or medical supply, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $139K
- Providers
- 1,987
- Transactions
- 3,235
- Average per transaction
- $43
The per-transaction average — $43 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,987 providers the average total is $70, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $86,240 | 62.0% |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $52,712 | 37.9% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $129 | 0.1% |